Geographic driver: The press release is anchored in San Antonio, Texas, and the only region explicitly highlighted is the United States (North America). The back‑to‑back record months in June and July stem from a surge in domestic demand for the CyPath® Lung test—particularly in the U.S. health‑system rollout and in key state‑level screening programs that have been expanding in Texas and other large‑population states. No other continents or regions are mentioned, so the U.S. market is the clear catalyst behind the sales lift.
Trading implications: The U.S.‑centric sales momentum underpins a strong fundamental tailwind for bioAffinity Technologies (BIAF). With a 70‑point positive sentiment score and two consecutive record months, the stock is likely to attract short‑term buying pressure, especially on the upside‑biased news‑flow. Technically, the recent price action should be tested against the June‑July rally; a break above the recent high could signal continuation, while a pull‑back toward the 20‑day moving average may offer a lower‑risk entry. Keep an eye on any announcements of international roll‑outs—if the company expands beyond North America, the upside could be even more pronounced, but for now the U.S. market is the primary driver of growth.